Racial and ethnic equity in PAH clinical trials

Robyn Kalda
Dec 22, 2025
1 min read

Looking at the racial and ethnic breakdown of patients with PAH and patients who take part in clinical trials, the authors conclude that the goal of equitable representation has not yet been reached.

The article includes a useful table of potential barriers to inclusive clinical trials and potential solutions.

Read the Advances in Pulmonary Hypertension article

Recent Posts

Start up: Supporting PAH patients beginning prostanoids

This study looked at a French support program designed to help people with pulmonary arterial hypertension (PAH) start and adjust their dose of selexipag. Nurses called patients three days after patie

Sotatercept vs. selexipag in severe PAH

Researchers used AI to indirectly compare data from three randomized controlled trials looking at sotatercept or selexipag in pulmonary arterial hypertension (PAH). Their findings suggest that sotater

Screening for PH in ILD

This study looked at how to better detect pulmonary hypertension (PH) in people with interstitial lung disease (ILD), since PH often makes breathing problems, quality of life, and survival worse. Rese

Comments